Drug intelligence / Profile preview

Shengfa peptide

Development stage: Unknown
Lead developer: Zhaoke Pharmaceutical
Modality: Peptides
Administration: Ophthalmic

Overview

Shengfa peptide is a synthetic peptide therapeutic developed by Zhaoke Pharmaceutical (a subsidiary of Lee's Pharmaceutical) for the treatment of ophthalmic conditions, specifically dry eye disease and corneal epithelial defects. The peptide is designed to promote the migration and proliferation of corneal epithelial cells, thereby accelerating the healing of corneal wounds and restoring the integrity of the ocular surface. It is formulated as a topical ophthalmic solution. Clinical development has focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers and patients with corneal damage, positioning it as a potential regenerative therapy for ocular surface disorders.

Other names: Shengfa peptide ophthalmic solution生发肽

Beyond the preview

Go deeper on Shengfa peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shengfa peptide.

Explore the full profile